Free Trial

Metagenomi (MGX) Competitors

Metagenomi logo
$2.89 +0.11 (+3.96%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$2.87 -0.02 (-0.69%)
As of 10/24/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MGX vs. MRNA, SLDB, DRUG, MBX, PRTC, AUTL, NGNE, EOLS, BNTC, and AMRN

Should you be buying Metagenomi stock or one of its competitors? The main competitors of Metagenomi include Moderna (MRNA), Solid Biosciences (SLDB), Bright Minds Biosciences (DRUG), MBX Biosciences (MBX), PureTech Health (PRTC), Autolus Therapeutics (AUTL), Neurogene (NGNE), Evolus (EOLS), Benitec Biopharma (BNTC), and Amarin (AMRN). These companies are all part of the "pharmaceutical products" industry.

Metagenomi vs. Its Competitors

Metagenomi (NASDAQ:MGX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

Moderna has a net margin of -94.31% compared to Metagenomi's net margin of -257.99%. Moderna's return on equity of -25.96% beat Metagenomi's return on equity.

Company Net Margins Return on Equity Return on Assets
Metagenomi-257.99% -37.84% -27.15%
Moderna -94.31%-25.96%-20.09%

In the previous week, Moderna had 46 more articles in the media than Metagenomi. MarketBeat recorded 52 mentions for Moderna and 6 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.98 beat Moderna's score of -0.03 indicating that Metagenomi is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Metagenomi
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Moderna
9 Very Positive mention(s)
4 Positive mention(s)
8 Neutral mention(s)
6 Negative mention(s)
6 Very Negative mention(s)
Neutral

Metagenomi has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, Moderna has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500.

Metagenomi has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Metagenomi$52.29M2.07-$78.06M-$2.36-1.22
Moderna$3.24B3.23-$3.56B-$7.53-3.55

75.3% of Moderna shares are held by institutional investors. 17.8% of Metagenomi shares are held by company insiders. Comparatively, 10.9% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Metagenomi presently has a consensus target price of $10.00, suggesting a potential upside of 246.02%. Moderna has a consensus target price of $36.86, suggesting a potential upside of 37.84%. Given Metagenomi's stronger consensus rating and higher probable upside, equities research analysts plainly believe Metagenomi is more favorable than Moderna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Metagenomi
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80
Moderna
5 Sell rating(s)
12 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.00

Summary

Moderna beats Metagenomi on 8 of the 15 factors compared between the two stocks.

Get Metagenomi News Delivered to You Automatically

Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MGX vs. The Competition

MetricMetagenomiMED IndustryMedical SectorNASDAQ Exchange
Market Cap$108.47M$2.63B$6.22B$10.81B
Dividend YieldN/A57.77%5.72%4.81%
P/E Ratio-1.2227.9431.5030.91
Price / Sales2.07786.96594.92133.93
Price / CashN/A168.8137.2561.86
Price / Book0.465.6512.056.61
Net Income-$78.06M$33.06M$3.34B$277.10M
7 Day Performance-5.25%3.16%1.93%2.57%
1 Month Performance25.65%8.14%7.77%3.79%
1 Year Performance44.50%-2.49%56.40%33.01%

Metagenomi Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MGX
Metagenomi
2.9799 of 5 stars
$2.89
+4.0%
$10.00
+246.0%
+50.5%$108.47M$52.29M-1.22236News Coverage
Analyst Upgrade
MRNA
Moderna
4.1833 of 5 stars
$27.24
+4.7%
$39.93
+46.6%
-49.4%$10.16B$3.24B-3.625,800Trending News
Analyst Forecast
Analyst Revision
SLDB
Solid Biosciences
2.9673 of 5 stars
$6.15
+4.6%
$15.00
+143.9%
+0.5%$457.87M$8.09M-2.20100News Coverage
Analyst Forecast
DRUG
Bright Minds Biosciences
3.1828 of 5 stars
$65.71
+4.1%
$81.00
+23.3%
+23.6%$444.76MN/A-70.66N/APositive News
MBX
MBX Biosciences
3.5046 of 5 stars
$14.23
+7.6%
$44.00
+209.2%
N/A$444.11MN/A-3.13N/APositive News
Analyst Forecast
Insider Trade
PRTC
PureTech Health
0.3223 of 5 stars
$18.29
+1.6%
N/A-15.0%$435.03M$4.83M0.00100Positive News
Analyst Forecast
Gap Up
AUTL
Autolus Therapeutics
3.7682 of 5 stars
$1.70
+4.9%
$9.12
+436.5%
-65.5%$431.15M$10.12M-2.02330Analyst Forecast
NGNE
Neurogene
1.8612 of 5 stars
$32.16
+10.8%
$46.17
+43.6%
-38.0%$414.32MN/A-7.4690Analyst Forecast
EOLS
Evolus
4.1201 of 5 stars
$6.69
+4.5%
$21.25
+217.6%
-57.0%$413.99M$266.27M-6.83170
BNTC
Benitec Biopharma
1.6657 of 5 stars
$16.23
+3.7%
$24.80
+52.8%
+51.1%$410.82M$80K-11.0420News Coverage
Analyst Forecast
AMRN
Amarin
0.9759 of 5 stars
$20.25
+3.1%
$12.00
-40.7%
+71.5%$406.21M$228.61M-5.52360News Coverage
Upcoming Earnings
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:MGX) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners